Wednesday, December 11, 2019
News on Pathogens and Preparedness
Global Biodefense
No Result
View All Result
  • Featured
  • Pathogens

    Tracing the Ancestral Genome of The Plague

    Aalto Bio Reagents Launches Protein for Detection of Venezuela Equine Encephalitis Virus

    Aalto Bio Reagents Launches Protein for Detection of Venezuela Equine Encephalitis Virus

    African Swine Fever: An Unexpected Threat to the Global Supply of Heparin

    African Swine Fever: An Unexpected Threat to the Global Supply of Heparin

    Bacillus anthracis concept drawing

    Decontamination of Bacillus Spores from Drinking Water Infrastructure

    MERS-CoV: Novel Zoonotic Disease Outbreak a Hard Lesson for Healthcare

    MERS-CoV: Novel Zoonotic Disease Outbreak a Hard Lesson for Healthcare

    red agar plate with cultured bacteria

    Study Shows Virulence of B. pseudomallei Strain in Aerosol Model

    Turns Out, Bat Influenza Can Give You the Flu

    Turns Out, Bat Influenza Can Give You the Flu

    Crimean-Congo Hemorrhagic Fever

    Crimean Congo Countermeasures: Researchers Investigate CCHFV-RDRp

    Yersinia pestis

    Researchers Optimize Novel Hexaplex PCR Assay for Simultaneous Detection of Anthrax and Plague Pathogens

  • Directory
  • Job Board
  • Funding
    • Contracts + Grants
    • Funding Awards
    • Requests for Information
    • Industry News
  • Events
    • All Events
    • Conferences + Meetings
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Headlines
  • Subscribe
  • Featured
  • Pathogens

    Tracing the Ancestral Genome of The Plague

    Aalto Bio Reagents Launches Protein for Detection of Venezuela Equine Encephalitis Virus

    Aalto Bio Reagents Launches Protein for Detection of Venezuela Equine Encephalitis Virus

    African Swine Fever: An Unexpected Threat to the Global Supply of Heparin

    African Swine Fever: An Unexpected Threat to the Global Supply of Heparin

    Bacillus anthracis concept drawing

    Decontamination of Bacillus Spores from Drinking Water Infrastructure

    MERS-CoV: Novel Zoonotic Disease Outbreak a Hard Lesson for Healthcare

    MERS-CoV: Novel Zoonotic Disease Outbreak a Hard Lesson for Healthcare

    red agar plate with cultured bacteria

    Study Shows Virulence of B. pseudomallei Strain in Aerosol Model

    Turns Out, Bat Influenza Can Give You the Flu

    Turns Out, Bat Influenza Can Give You the Flu

    Crimean-Congo Hemorrhagic Fever

    Crimean Congo Countermeasures: Researchers Investigate CCHFV-RDRp

    Yersinia pestis

    Researchers Optimize Novel Hexaplex PCR Assay for Simultaneous Detection of Anthrax and Plague Pathogens

  • Directory
  • Job Board
  • Funding
    • Contracts + Grants
    • Funding Awards
    • Requests for Information
    • Industry News
  • Events
    • All Events
    • Conferences + Meetings
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Headlines
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

HHS Boosts Global Ability to Respond to Pandemics

by Global Biodefense
28 Oct 2013

To build a sustainable capacity to manufacture influenza vaccine in developing countries and help reduce the global threat of influenza pandemics, the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) recently announced grants totaling $15 million to two international organizations and two U.S. universities.

The awards are the latest in a program established by ASPR’s Biomedical Advanced Research and Development Authority (BARDA) in 2006 to accelerate development of locally produced influenza vaccines around the world. 

The program provides cost-sharing to build vaccine manufacturing facilities that can produce influenza and other vaccines in developing countries and trains personnel from developing countries at U.S.-based universities in advanced vaccine production. The program also supports technical assistance for foreign countries to operate and regulate their facilities and to conduct clinical trials with influenza vaccines produced in the facilities. 

“Making more vaccine available worldwide during pandemics makes everyone safer,” said BARDA Director Robin Robinson, Ph.D. “By enhancing the manufacturing capacity in developing countries, we strengthen the overall global pandemic response capabilities and enhance America’s health security.”

The World Health Organization (WHO) will receive $10.5 million to support its Global Action Plan for Influenza Vaccines (GAP). GAP enhances capacity to produce influenza vaccines in low-resourced nations. The BARDA funding supports H7N9-related preparedness activities, allowing manufacturers in these countries to produce H7N9 pre-pandemic influenza vaccine candidates and to evaluate vaccine safety and efficacy in clinical studies.

Over the past seven years, BARDA has provided approximately $50 million through this WHO initiative to support development of influenza vaccine manufacturing capacity in Brazil, Egypt, India, Indonesia, Kazakhstan, Mexico, Romania, Serbia, South Africa, South Korea, Thailand, and Vietnam. 

This initiative has led to approval in these countries of three seasonal flu vaccines and seven 2009 H1N1 pandemic vaccines and has resulted in two vaccines being pre-qualified by the WHO for use in a pandemic. Several of the developing countries were able to respond to the 2009 H1N1 pandemic with high quality locally produced vaccines because of advances made through the program.

In addition, BARDA will provide $4.25 million to PATH, an international global health non-governmental organization. Through this grant, PATH will provide specialized technical support on-site to assist influenza vaccine manufacturers in troubleshooting and remediating any issues with their manufacturing processes and will help in advanced clinical development of influenza vaccines.

To develop and maintain a skilled global workforce capable of producing vaccines, BARDA will continue to support the biomanufacturing training program for vaccine manufacturers in developing countries. This support allows for on-site training and practical hands-on programs in biomanufacturing and current Good Manufacturing Practices.

Utah State University’s Center for Integrated Biosystems in Logan, and North Carolina State University’s Biotechnology and Education Center in Raleigh will receive $125,000 each to conduct these training programs.

BARDA’s international influenza program compliments the agency’s efforts to build influenza vaccine manufacturing capacity domestically and to develop new, faster technologies for producing a greater quantity of effective vaccines in the United States. 

These international and domestic programs are part of BARDA’s comprehensive, integrated portfolio approach to the advanced research and development, innovation, acquisition, and manufacturing of vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products for public health emergency threats. In addition to pandemic influenza and emerging infectious diseases, these threats include chemical, biological, radiological and nuclear agents.

Source: HHS

Tags: AwardsBARDABiodetectionInfluenzaPandemicVaccines
Previous Post

Flu Virus Wipes Out Immune System's First Responders

Next Post

Innovative Platforms for Countermeasure Development - First Interim Deadline Extended

Related Posts

Interview: Ambassador Bonnie Jenkins on 8 years of Combating WMD Terrorism
Health Security

Interview: Ambassador Bonnie Jenkins on 8 years of Combating WMD Terrorism

3 Dec 2019
There’s No Such Thing as Just-in-Time Healthcare and Public Health Preparedness
Health Security

There’s No Such Thing as Just-in-Time Healthcare and Public Health Preparedness

28 Nov 2019
Salad Bars and Water Systems are Easy Targets for Bioterrorists – and America’s Monitoring System is Woefully Inadequate
Biosecurity

Salad Bars and Water Systems are Easy Targets for Bioterrorists – and America’s Monitoring System is Woefully Inadequate

17 Nov 2019
Diagnosing Sepsis in Minutes: Cytovale Raises $15 Million in Financing
Biodetection

Diagnosing Sepsis in Minutes: Cytovale Raises $15 Million in Financing

9 Nov 2019
Philips and DoD Develop Breakthrough Tech to Identify Infection 48 hours Before Observable Symptoms
Preparedness

Philips and DoD Develop Breakthrough Tech to Identify Infection 48 hours Before Observable Symptoms

22 Oct 2019
test plate 96 well bioassay
Funding News

BioFactura’s Smallpox Biodefense Therapeutic Awarded $67M BARDA Contract

26 Sep 2019
Load More
Next Post

Innovative Platforms for Countermeasure Development - First Interim Deadline Extended

Headlines

  • Artificial Intelligence and Big Data Analytics for Biodefence: Implications for Threat Assessment And Biosurveillance
  • African Swine Fever Kills More Than 20 Wild Boar in Poland
  • Samoa Measles Outbreak: Death Toll Rises To 53, Mostly Children
  • OPCW Defends Syria Attack Conclusions After Document Leaks
  • Osama bin Laden’s “Anthrax Scientist” Freed by Malaysia

Recommended

  • Highly Sensitive Epigenomic Technology Combats Disease
  • Interview: Ambassador Bonnie Jenkins on 8 years of Combating WMD Terrorism
  • There’s No Such Thing as Just-in-Time Healthcare and Public Health Preparedness
  • Threat Detection in Your Pocket
  • Inflammatix Wins BARDA Backing for Diagnostic to Rapidly Distinguish Bacterial from Viral Infections

Featured Partner

  • About
  • Contact
  • Privacy
  • Subscribe

© 2019 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • Pathogens
  • Directory
  • Job Board
  • Funding
    • Contracts + Grants
    • Funding Awards
    • Requests for Information
    • Industry News
  • Events
    • All Events
    • Conferences + Meetings
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Headlines
  • Subscribe

© 2019 Stemar Media Group LLC